about
Toward rapamycin analog (rapalog)-based precision cancer therapyRoles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implicationsSomatic Activating PIK3CA Mutations Cause Venous MalformationSignaling by the phosphoinositide 3-kinase family in immune cellsPhysiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumorsNetwork Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsyMacrophage Apoptosis and Efferocytosis in the Pathogenesis of AtherosclerosisBI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting AktDiagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.Structural basis of nSH2 regulation and lipid binding in PI3Kα.Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin.High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinomaMultiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient sourceComprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profilingHigh-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer.PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse modelsPIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking.Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.AKT-independent PI3-K signaling in cancer - emerging role for SGK3.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts.AR Signaling and the PI3K Pathway in Prostate CancerCombined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.Hierarchy and Plasticity in the Intestinal Stem Cell Compartment.Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.Application of Machine Learning to Development of Copy Number Variation-based Prediction of Cancer RiskERBB4 mutation analysis: emerging molecular target for melanoma treatment.Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase modelAKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.Editorial: cell movement.
P2860
Q26795606-4D7A4565-6531-4222-89EA-D1F1787C5214Q27009016-C7CCAA90-AFB3-4E4A-98DA-1457196F696AQ28270654-607B8748-67BA-4A62-8705-BA2FEF323F00Q28283677-3E14DCEA-6EA1-4509-8D41-B04B82BCE00FQ28729079-07DBA45E-3222-4481-8A73-354F65E12126Q33631628-9E177EB7-74C7-4622-9DA9-0C775EC25FDFQ33687799-3F7FD6DA-E208-4ED6-80B9-CA1C4563534EQ33764821-DF27A546-C4D8-4B9D-9182-709DFB949C0CQ33877402-0FC5E475-2D23-4514-A683-719F6B01CB90Q34109055-DE8A27F5-A691-4246-8EF5-C71E22CF7844Q34221876-7BB341E2-4C47-4107-B797-BC728E4AA5F9Q34264934-0657F4B6-AB62-44FE-AA13-871B36A977EBQ34314010-316A93A2-016B-4B4B-8057-D97BD293E1B4Q34427978-EDC8E028-ECF9-435A-A2D7-08320822B6C6Q34737562-4AEFA758-6CCA-48F3-9A09-77A06D3743B7Q36184195-5D0A8D1F-F3EF-4029-B7B1-55DE3368A94DQ36244792-7675F25A-5608-4400-B22D-55C9C48A2BB5Q36361515-95F39386-4B56-43A8-A02F-3C3759669F9AQ36371231-B45A5DA7-905A-43B4-AB10-1F0538F44F3CQ36552676-683986D9-1AF4-4261-A78F-5BC3ED950982Q37167731-D505388C-6F40-4FB6-AD27-60D411359E87Q37479076-40D32BF2-A0E3-4322-86BC-862C9DB3021CQ37702222-5F69F7A1-810C-4E60-963D-B846D30401E8Q37728444-70328A4E-1440-4ADE-8F0D-34136C2E480BQ37951937-BB22598A-DE5F-4296-ACE2-F1D0FFADB941Q37968309-0680FA2C-BDE1-469A-8311-BEF7D6E70012Q38059212-4AD6D351-361A-44A2-949C-A72F4B0CDF1EQ38134714-812F33EC-17AC-4001-8BB0-58854CDE99BAQ38175044-980E9257-9F34-4AAC-9CD3-A81BFF9CFB01Q38880117-43EB568A-EC3F-4462-970B-3A4C3608E8ACQ39206695-F3F073B5-2381-4647-BF2F-0E54E35D3653Q39249001-59CE5F9E-D83B-456C-BE46-174CB66E25A4Q39277209-E60C5562-4713-4AF5-9E24-948088066BA2Q39451028-F5ED1CCE-EC38-464D-A065-EB8FAD9F674EQ41471269-CBC05B34-B623-442B-8A1D-DF87BE0F90DDQ41715498-81F0C3C8-7D32-4E4F-AC76-7E096987C405Q42012553-94B6E06B-0703-4170-9DD8-D4D648F6C6D0Q42316429-3BFCFFE0-5B40-4A32-AF08-E76BC2C31C1CQ42445998-ABFF8ECB-6662-4D64-9CB7-88A001330B8FQ42703098-2491DB11-0EA8-4461-B23D-DA2150C42F33
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oncogenic mutations of PIK3CA in human cancers
@ast
Oncogenic mutations of PIK3CA in human cancers
@en
Oncogenic mutations of PIK3CA in human cancers
@nl
type
label
Oncogenic mutations of PIK3CA in human cancers
@ast
Oncogenic mutations of PIK3CA in human cancers
@en
Oncogenic mutations of PIK3CA in human cancers
@nl
prefLabel
Oncogenic mutations of PIK3CA in human cancers
@ast
Oncogenic mutations of PIK3CA in human cancers
@en
Oncogenic mutations of PIK3CA in human cancers
@nl
P2860
P356
P1476
Oncogenic mutations of PIK3CA in human cancers
@en
P2093
Todd Waldman
Yardena Samuels
P2860
P356
10.1007/82_2010_68
P407
P577
2010-01-01T00:00:00Z